DBS and VNS achieve only 3-9% of addressable patient populations — structural analysis reveals scale of undertreatment
Summary
A structural analysis published in the Protocol Labs BCI Roadmap and cited in the Neurotech Futures commercial insights report found that established, commercially available neuromodulation therapies including deep brain stimulation and vagus nerve stimulation achieve only 3-9% penetration of their medically addressable patient populations. For DBS in Parkinson's disease alone, this means approximately 90% of patients who could clinically benefit from DBS never receive it, due to physician workflow barriers, patient reluctance about brain surgery, insufficient trained neurosurgeons, and geographic access constraints.
Why it matters
Three to nine percent penetration of addressable patients is the most important underappreciated fact in neuromodulation — it means the entire commercial opportunity for DBS, SCS, VNS, and future BCIs depends not primarily on developing better devices but on removing the structural barriers to adoption. Minimally invasive surgery, simplified programming, at-home use, and better physician education are worth more commercially than incremental device performance improvements.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial